RCE
Director Trades
| Date | Director | Value |
|---|---|---|
| 15/5/25 | J. Prendergast | $14,318 |
| 15/5/25 | J. Graham | $10,000 |
| 15/5/25 | J. Ward | $14,067 |
| 15/5/25 | M. Dilizia | $5,000 |
| 15/5/25 | A. Dunton | $5,451 |
| 15/5/25 | A. McKeough | $1,211 |
Company News
Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections
Recce Pharmaceuticals (ASX: RCE) has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel (R327G) to treat diabetic foot infections (DFI). The company has activated five clinical study sites across one of the world’s largest DFI patient populations in Indonesia, where estimates place the prevalence of diabetes at 20.9 […]
ASX Investment Opportunities on Show in Singapore During Grand Prix
All roads will lead to Singapore in early October with the important Spark Plus Aussie Equities Day investment show being staged in the lead-up to the local grand prix motoring event. The 2025 Spark Plus Aussie Equities Day is the 4th installment of their flagship event which aims to introduce a range of Australian companies to […]
Recce Pharmaceuticals releases positive data from Phase II trial of topical gel for skin infections
Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections. The company designed the open-label trial to assess the efficacy and safety of R327G in 30 male and female patients, with […]
Recce Pharmaceuticals expands COVID-19 screening program via US-based study
One week since announcing two of its compounds will be used in an upcoming antiviral SARS-CoV-2 screening program, Recce Pharmaceuticals (ASX: RCE) has penned an agreement with US-based precision medicine company Path BioAnalytics for the study of its RECCE 327 and RECCE 529 antibiotics against SARS-CoV-2, the strain of coronavirus that causes COVID-19. The development […]
Recce Pharmaceuticals’ formulations to be evaluated as potential treatment for COVID-19
Recce Pharmaceuticals (ASX: RCE) emerged from a trading halt to announced that two of its drug candidates would be used in an upcoming antiviral SARS-Cov-2 screening program. The pharma company is attempting to develop and commercialise new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral […]
Recce Pharma reports positive data from anti-viral drug trial for Influenza A, signs agreement for first-in-human study
A study into a new class of synthetic antibiotics developed by Recce Pharmaceuticals (ASX: RCE) has produced positive data showing significant in vivo anti-viral activity against the Influenza A virus in mice being treated with the company’s patented lead compound Recce 327. Data from the study involving four groups of 12 mice infected with Influenza A showed a significant […]
Recce Pharmaceuticals’ new class antibiotic effective in treating urinary tract infections during pre-clinical trials
Frequent urinary tract infection (UTI) and kidney infection sufferers may have some relief after Recce Pharmaceuticals (ASX: RCE) revealed pre-clinical trials had demonstrated its new class broad spectrum antibiotics were effective against one of the primary causes E. coli bacteria. Recce trialled its RECCE 327 antibiotic in rat models afflicted with E. coli (gram negative) […]
Recce Pharmaceuticals locks-in US patent for synthetic antibiotic to target growing superbug problem
Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the company to shoulder into the US$42.33 billion global antibiotic market. The new class of synthetic antibiotics were developed to address the mounting existence of antibiotic-resistant superbugs. Following from the company’s first ever wholly-owned US patent, the […]